Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
6705 | 1453 | 33.1 | 50% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
176 | 3 | DIABETES CARE//ENDOCRINOLOGY & METABOLISM//TYPE 2 DIABETES | 58057 |
1896 | 2 | METFORMIN//ACARBOSE//REPAGLINIDE | 5944 |
6705 | 1 | GLIMEPIRIDE//JTT 608//SECONDARY FAILURE | 1453 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | GLIMEPIRIDE | authKW | 242369 | 4% | 19% | 60 |
2 | JTT 608 | authKW | 126082 | 0% | 100% | 6 |
3 | SECONDARY FAILURE | authKW | 111298 | 1% | 38% | 14 |
4 | SULFONYLUREA | authKW | 89099 | 5% | 6% | 68 |
5 | GLUCAGON TEST | authKW | 61121 | 1% | 36% | 8 |
6 | C PEPTIDE | authKW | 52597 | 3% | 5% | 46 |
7 | CAS 93479 97 1 | authKW | 48028 | 0% | 57% | 4 |
8 | INSULIN REQUIRING DIABETES | authKW | 48028 | 0% | 57% | 4 |
9 | HOE 490 | authKW | 47279 | 0% | 75% | 3 |
10 | GLIPIZIDE | authKW | 44674 | 1% | 11% | 20 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 23238 | 49% | 0% | 705 |
2 | Medicine, General & Internal | 2691 | 21% | 0% | 303 |
3 | Pharmacology & Pharmacy | 1033 | 18% | 0% | 256 |
4 | Medicine, Research & Experimental | 197 | 6% | 0% | 80 |
5 | Primary Health Care | 78 | 1% | 0% | 12 |
6 | Nutrition & Dietetics | 51 | 2% | 0% | 32 |
7 | Medical Laboratory Technology | 50 | 1% | 0% | 18 |
8 | Geriatrics & Gerontology | 46 | 1% | 0% | 18 |
9 | Toxicology | 9 | 2% | 0% | 23 |
10 | Chemistry, Medicinal | 8 | 2% | 0% | 22 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | AIR WING | 21014 | 0% | 100% | 1 |
2 | ANITDIABET UNIT | 21014 | 0% | 100% | 1 |
3 | BIOANALYT BIOTRANSFORMAT | 21014 | 0% | 100% | 1 |
4 | BU DIABETOL | 21014 | 0% | 100% | 1 |
5 | CATTEDRA NEFROL MED PATOL MED | 21014 | 0% | 100% | 1 |
6 | CHAIR ENDOCRINOLIST AUXOL ITALIANOIRCCS | 21014 | 0% | 100% | 1 |
7 | DERBYSHIRE ROYAL INFIRM NHS TRUST | 21014 | 0% | 100% | 1 |
8 | DIABET EDU PROGRAMS | 21014 | 0% | 100% | 1 |
9 | DIABET MELLITUS ENDOCRINE | 21014 | 0% | 100% | 1 |
10 | DIABET TREATMENT TEACHING UNIT | 21014 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | DIABETES CARE | 24323 | 8% | 1% | 115 |
2 | DIABETES & METABOLISM | 23127 | 4% | 2% | 56 |
3 | ACTA DIABETOLOGICA LATINA | 17283 | 1% | 4% | 19 |
4 | DIABETES RESEARCH AND CLINICAL PRACTICE | 12387 | 4% | 1% | 56 |
5 | HORMONE AND METABOLIC RESEARCH | 9283 | 4% | 1% | 53 |
6 | DIABETES | 6658 | 4% | 1% | 62 |
7 | DIABETIC MEDICINE | 6461 | 3% | 1% | 42 |
8 | METABOLISM-CLINICAL AND EXPERIMENTAL | 6356 | 4% | 1% | 52 |
9 | ACTA ENDOCRINOLOGICA | 6165 | 2% | 1% | 34 |
10 | DIABETES RESEARCH CLINICAL AND EXPERIMENTAL | 4416 | 1% | 2% | 11 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | GLIMEPIRIDE | 242369 | 4% | 19% | 60 | Search GLIMEPIRIDE | Search GLIMEPIRIDE |
2 | JTT 608 | 126082 | 0% | 100% | 6 | Search JTT+608 | Search JTT+608 |
3 | SECONDARY FAILURE | 111298 | 1% | 38% | 14 | Search SECONDARY+FAILURE | Search SECONDARY+FAILURE |
4 | SULFONYLUREA | 89099 | 5% | 6% | 68 | Search SULFONYLUREA | Search SULFONYLUREA |
5 | GLUCAGON TEST | 61121 | 1% | 36% | 8 | Search GLUCAGON+TEST | Search GLUCAGON+TEST |
6 | C PEPTIDE | 52597 | 3% | 5% | 46 | Search C+PEPTIDE | Search C+PEPTIDE |
7 | CAS 93479 97 1 | 48028 | 0% | 57% | 4 | Search CAS+93479+97+1 | Search CAS+93479+97+1 |
8 | INSULIN REQUIRING DIABETES | 48028 | 0% | 57% | 4 | Search INSULIN+REQUIRING+DIABETES | Search INSULIN+REQUIRING+DIABETES |
9 | HOE 490 | 47279 | 0% | 75% | 3 | Search HOE+490 | Search HOE+490 |
10 | GLIPIZIDE | 44674 | 1% | 11% | 20 | Search GLIPIZIDE | Search GLIPIZIDE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | GERICH, JE , (1989) DRUG-THERAPY - ORAL HYPOGLYCEMIC AGENTS.NEW ENGLAND JOURNAL OF MEDICINE. VOL. 321. ISSUE 18. P. 1231 -1245 | 91 | 61% | 392 |
2 | FURLONG, NJ , GOUDSWAARD, AN , VALK, GD , STOLK, RP , RUTTEN, GEHM , (2004) INSULIN MONOTHERAPY VERSUS COMBINATIONS OF INSULIN WITH ORAL HYPOGLYCAEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 4. P. - | 73 | 55% | 24 |
3 | GROOP, LC , (1992) SULFONYLUREAS IN NIDDM.DIABETES CARE. VOL. 15. ISSUE 6. P. 737-754 | 69 | 59% | 332 |
4 | RENDELL, M , (2004) THE ROLE OF SULPHONYLUREAS IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS.DRUGS. VOL. 64. ISSUE 12. P. 1339-1358 | 82 | 31% | 145 |
5 | SIMONSON, DC , KOURIDES, IA , FEINGLOS, M , SHAMOON, H , FISCHETTE, CT , ARONOFF, S , BLONDE, L , CEFALU, W , CLEMENT, S , GREENBERG, C , ET AL (1997) EFFICACY, SAFETY, AND DOSE-RESPONSE CHARACTERISTICS OF GLIPIZIDE GASTROINTESTINAL THERAPEUTIC SYSTEM ON GLYCEMIC CONTROL AND INSULIN SECRETION IN NIDDM - RESULTS OF TWO MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIALS.DIABETES CARE. VOL. 20. ISSUE 4. P. 597-606 | 39 | 81% | 87 |
6 | JOHNSON, JL , WOLF, SL , KABADI, UM , (1996) EFFICACY OF INSULIN AND SULFONYLUREA COMBINATION THERAPY IN TYPE II DIABETES - A META-ANALYSIS OF THE RANDOMIZED PLACEBO-CONTROLLED TRIALS.ARCHIVES OF INTERNAL MEDICINE. VOL. 156. ISSUE 3. P. 259-264 | 31 | 89% | 90 |
7 | PETERS, AL , DAVIDSON, MB , (1991) INSULIN PLUS A SULFONYLUREA AGENT FOR TREATING TYPE-2 DIABETES.ANNALS OF INTERNAL MEDICINE. VOL. 115. ISSUE 1. P. 45-53 | 40 | 87% | 57 |
8 | GENUTH, S , (1990) INSULIN USE IN NIDDM.DIABETES CARE. VOL. 13. ISSUE 12. P. 1240 -1264 | 76 | 44% | 105 |
9 | BRISCOE, VJ , GRIFFITH, ML , DAVIS, SN , (2010) THE ROLE OF GLIMEPIRIDE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 6. ISSUE 2. P. 225-235 | 28 | 68% | 7 |
10 | JONES, AG , HATTERSLEY, AT , (2013) THE CLINICAL UTILITY OF C-PEPTIDE MEASUREMENT IN THE CARE OF PATIENTS WITH DIABETES.DIABETIC MEDICINE. VOL. 30. ISSUE 7. P. 803 -817 | 40 | 36% | 45 |
Classes with closest relation at Level 1 |